RACHEL ROWLAND: Open Payments
NPI 1548403454 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,034 in 21 payments from 8 companies in 2025. Trend: 2023 $1,942 · 2024 $1,300 · 2025 $1,034
Food & beverage: $1,034
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $239 |
| Gilead Sciences, Inc. | 7 | $220 |
| ViiV Healthcare Company | 6 | $149 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $112 |
| ABBVIE INC. | 1 | $111 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| EMD Serono, Inc. | 1 | $35 |
Products named: JARDIANCE, REXULTI, CABENUVA, XIFAXAN, VRAYLAR, Biktarvy, PIFELTRO, DOVATO.
Industry payments across LA — which companies pay providers there.
